Comparing Talaris Therapeutics (NASDAQ:TALS) and Finch Therapeutics Group (NASDAQ:FNCH)

Talaris Therapeutics (NASDAQ:TALSGet Rating) and Finch Therapeutics Group (NASDAQ:FNCHGet Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Talaris Therapeutics and Finch Therapeutics Group, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talaris Therapeutics 0 2 1 0 2.33
Finch Therapeutics Group 0 0 2 0 3.00

Talaris Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 357.52%. Finch Therapeutics Group has a consensus price target of $17.00, indicating a potential upside of 701.89%. Given Finch Therapeutics Group’s stronger consensus rating and higher probable upside, analysts plainly believe Finch Therapeutics Group is more favorable than Talaris Therapeutics.

Insider and Institutional Ownership

68.0% of Talaris Therapeutics shares are held by institutional investors. Comparatively, 20.7% of Finch Therapeutics Group shares are held by institutional investors. 16.6% of Talaris Therapeutics shares are held by insiders. Comparatively, 44.6% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Talaris Therapeutics and Finch Therapeutics Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Talaris Therapeutics N/A -27.17% -26.18%
Finch Therapeutics Group -592.95% -40.10% -34.23%

Earnings and Valuation

This table compares Talaris Therapeutics and Finch Therapeutics Group’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Talaris Therapeutics N/A N/A -$47.83 million ($1.52) -2.01
Finch Therapeutics Group $18.53 million 5.46 -$58.16 million ($1.61) -1.32

Talaris Therapeutics has higher earnings, but lower revenue than Finch Therapeutics Group. Talaris Therapeutics is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Talaris Therapeutics has a beta of 3.08, indicating that its stock price is 208% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of -0.7, indicating that its stock price is 170% less volatile than the S&P 500.

Summary

Talaris Therapeutics beats Finch Therapeutics Group on 7 of the 13 factors compared between the two stocks.

About Talaris Therapeutics

(Get Rating)

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

About Finch Therapeutics Group

(Get Rating)

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.